company background image

vTv Therapeutics NasdaqCM:VTVT Stock Report

Last Price


Market Cap







15 Aug, 2022


Company Financials +
VTVT fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

VTVT Stock Overview

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes.

vTv Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for vTv Therapeutics
Historical stock prices
Current Share PriceUS$1.37
52 Week HighUS$2.17
52 Week LowUS$0.38
1 Month Change100.88%
3 Month Change211.36%
1 Year Change-20.35%
3 Year Change6.20%
5 Year Change-68.65%
Change since IPO-87.42%

Recent News & Updates

Jul 25

vTv stock soars 18% on $10M equity investment by CinRx Pharma

vTv Therapeutics (NASDAQ:VTVT) is raising $10M via an equity investment by CinPax, a unit of CinRx Pharma. Under the agreements, CinPax acquired ~4.15M class A Common shares of vTv at ~$2.41 apiece. About $6M will be paid in cash at closing, and the remaining $4M payable on Nov. 22. vTv will also issue 1.2M warrants to to CinRx to acquire additional class A shares which become exercisable upon agreed vesting triggers (including FDA approval of TTP399. vTv said it will use CinRx's industry experience to collaborate on the oversight of clinical trials for pharmaceutical products that contain TTP399. VTVT +18.70% to $0.85 premarket July 25

Shareholder Returns

VTVTUS BiotechsUS Market

Return vs Industry: VTVT exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: VTVT underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is VTVT's price volatile compared to industry and market?
VTVT volatility
VTVT Average Weekly Movement13.1%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: VTVT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: VTVT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

20159Paul Sekhri

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners.

vTv Therapeutics Inc. Fundamentals Summary

How do vTv Therapeutics's earnings and revenue compare to its market cap?
VTVT fundamental statistics
Market CapUS$141.42m
Earnings (TTM)-US$15.75m
Revenue (TTM)US$5.02m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VTVT income statement (TTM)
Cost of RevenueUS$12.54m
Gross Profit-US$7.52m
Other ExpensesUS$8.23m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.19
Gross Margin-149.90%
Net Profit Margin-313.93%
Debt/Equity Ratio0%

How did VTVT perform over the long term?

See historical performance and comparison